ACST Acasti Pharma Inc.

2.16
-0.02  -1%
Previous Close 2.18
Open 2.16
Price To Book 72
Market Cap 183,206,329
Shares 85,188,095
Volume 746,108
Short Ratio
Av. Daily Volume 1,211,263
Stock charts supplied by TradingView

NewsSee all news

  1. Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    LAVAL, Québec, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its

  2. Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

    Nearly 80% of randomized patients have completed the studies Data clean-up for TRILOGY 1 is 90% completed Plan to present full data set including results for key secondary and exploratory endpoints of interest such as

  3. Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity

    LAVAL, Quebec, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company")  (NASDAQ:ACST, TSXV:ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its

  4. Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th

    LAVAL, Québec, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its

  5. Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM

    LAVAL, Quebec, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data due in December 2019 (1) and January 2020 (2).
CaPre (TRILOGY 1 and 2)
Hypertriglyceridemia

Latest News

  1. Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    LAVAL, Québec, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its

  2. Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

    Nearly 80% of randomized patients have completed the studies Data clean-up for TRILOGY 1 is 90% completed Plan to present full data set including results for key secondary and exploratory endpoints of interest such as

  3. Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity

    LAVAL, Quebec, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company")  (NASDAQ:ACST, TSXV:ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its

  4. Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th

    LAVAL, Québec, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its

  5. Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM

    LAVAL, Quebec, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST, TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of